BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 9196247)

  • 21. Difficulty measuring methotrexate in a patient with high-dose methotrexate-induced nephrotoxicity.
    Al-Turkmani MR; Law T; Narla A; Kellogg MD
    Clin Chem; 2010 Dec; 56(12):1792-4. PubMed ID: 21119035
    [No Abstract]   [Full Text] [Related]  

  • 22. Case files of the New York City Poison Control Center: antidotal strategies for the management of methotrexate toxicity.
    Smith SW; Nelson LS
    J Med Toxicol; 2008 Jun; 4(2):132-40. PubMed ID: 18570175
    [No Abstract]   [Full Text] [Related]  

  • 23. Severe acute toxicity associated with high-dose methotrexate (MTX) therapy: use of therapeutic drug monitoring and test-dose to guide carboxypeptidase G2 rescue and MTX continuation.
    Estève MA; Devictor-Pierre B; Galy G; André N; Coze C; Lacarelle B; Bernard JL; Monjanel-Mouterde S
    Eur J Clin Pharmacol; 2007 Jan; 63(1):39-42. PubMed ID: 17115148
    [No Abstract]   [Full Text] [Related]  

  • 24. Reduced-dose carboxypeptidase-G2 successfully lowers elevated methotrexate levels in an adult with acute methotrexate-induced renal failure.
    Trifilio S; Ma S; Petrich A
    Clin Adv Hematol Oncol; 2013 May; 11(5):322-3. PubMed ID: 23880719
    [No Abstract]   [Full Text] [Related]  

  • 25. Delayed Methotrexate Clearance Despite Carboxypeptidase-G2 (Glucarpidase) Administration in 2 Patients With Toxic Methotrexate Levels.
    Wyatt KD; Cooper J; Scott K; Broomall E; Altaf S; Hogan MC; Rodriguez V; Khan S
    J Pediatr Hematol Oncol; 2018 Mar; 40(2):152-155. PubMed ID: 29240024
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Glucarpidase (carboxypeptidase g2) intervention in adult and elderly cancer patients with renal dysfunction and delayed methotrexate elimination after high-dose methotrexate therapy.
    Schwartz S; Borner K; Müller K; Martus P; Fischer L; Korfel A; Auton T; Thiel E
    Oncologist; 2007 Nov; 12(11):1299-308. PubMed ID: 18055849
    [TBL] [Abstract][Full Text] [Related]  

  • 27. What is the best therapy for toxicity in the setting of methotrexate-associated acute kidney injury: high-flux hemodialysis or carboxypeptidase G2?
    Kumar N; Shirali AC
    Semin Dial; 2014; 27(3):226-8. PubMed ID: 24620824
    [No Abstract]   [Full Text] [Related]  

  • 28. Renal dysfunction during and after high-dose methotrexate.
    Green MR; Chamberlain MC
    Cancer Chemother Pharmacol; 2009 Mar; 63(4):599-604. PubMed ID: 18504579
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effective removal of methotrexate by high-flux hemodialysis.
    Saland JM; Leavey PJ; Bash RO; Hansch E; Arbus GS; Quigley R
    Pediatr Nephrol; 2002 Oct; 17(10):825-9. PubMed ID: 12376811
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fixed-Dose Glucarpidase for Toxic Methotrexate Levels and Acute Kidney Injury in Adult Lymphoma Patients: Case Series.
    Truong H; Leung N
    Clin Lymphoma Myeloma Leuk; 2021 Jun; 21(6):e497-e502. PubMed ID: 33563580
    [No Abstract]   [Full Text] [Related]  

  • 31. Glucarpidase treatment for methotrexate intoxication: a case report and review of the literature.
    Boelens AD; Mathôt RAA; Vlaar APJ; Bouman CSC
    Neth J Med; 2018 Jan; 76(1):36-39. PubMed ID: 29380731
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Resumption of high-dose methotrexate after methotrexate-induced nephrotoxicity and carboxypeptidase G2 use.
    Snyder RL
    Am J Health Syst Pharm; 2007 Jun; 64(11):1163-9. PubMed ID: 17519458
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Renal toxicity of high-dose methotrexate].
    Garcia H; Leblond V; Goldwasser F; Bouscary D; Raffoux E; Boissel N; Broutin S; Joly D
    Nephrol Ther; 2018 Apr; 14 Suppl 1():S103-S113. PubMed ID: 29606256
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reply to: Glucarpidase for the Treatment of Methotrexate-Induced Renal Dysfunction and Delayed Methotrexate Excretion.
    Widemann BC
    Pediatr Blood Cancer; 2016 Feb; 63(2):366. PubMed ID: 26488622
    [No Abstract]   [Full Text] [Related]  

  • 35. Using a lower dose of glucarpidase to reduce plasma levels of methotrexate.
    Widemann BC
    Clin Adv Hematol Oncol; 2013 May; 11(5):324-5. PubMed ID: 23880720
    [No Abstract]   [Full Text] [Related]  

  • 36. Reversal of neurologic disturbances related to high-dose methotrexate by aminophylline.
    Peyriere H; Poiree M; Cociglio M; Margueritte G; Hansel S; Hillaire-Buys D
    Med Pediatr Oncol; 2001 Jun; 36(6):662-4. PubMed ID: 11344503
    [No Abstract]   [Full Text] [Related]  

  • 37. High-dose methotrexate-associated acute renal failure may be an avoidable complication.
    Fong CM; Lee AC
    Pediatr Hematol Oncol; 2006; 23(1):51-7. PubMed ID: 16326413
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intracerebral hematoma as a complication of intrathecal methotrexate administration.
    Boran P; Tokuc G; Boran BO; Oktem S
    Pediatr Blood Cancer; 2008 Jan; 50(1):152-4. PubMed ID: 16615061
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acral erythema with oral methotrexate in a child.
    Varela CR; McNamara J; Antaya RJ
    Pediatr Dermatol; 2007; 24(5):541-6. PubMed ID: 17958806
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Re: Maculopathy as a complication of blood-brain barrier disruption in patients with central nervous system lymphoma.
    Goldstein DA; Tessler HH
    Am J Ophthalmol; 2007 Dec; 144(6):976; author reply 976. PubMed ID: 18036877
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.